<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Ulcerative colitis; Colitis: ulcerative; Crohn's disease; Aminosalicylates; Balsalazide; Mesalazine; Olsalazine; Sulfasalazine; Corticosteroids: inflammatory bowel disease; Budesonide: inflammatory bowel disease; Budesonide: Crohn's; Beclometasone dipropionate: ulcerative colitis; Ciclosporin: ulcerative colitis; Mercaptopurine: inflammatory bowel disease; Methotrexate: Crohn's disease; Infliximab: Crohn's disease; Infliximab: ulcerative colitis; Adalimumab: Crohn's disease; Adalimumab: ulcerative colitis; Azathioprine: inflammatory bowel disease; Crohn's disease: fistulating; Metronidazole: Crohn's disease; Ciprofloxacin: Crohn's disease; Azathioprine: inflammatory bowel disease; Mercaptopurine: inflammatory bowel disease; Infliximab: Crohn's disease; Adalimumab: Crohn's disease" /><meta name="IX" content="Ulcerative colitis; Colitis: ulcerative; Crohn's disease; Aminosalicylates; Balsalazide; Mesalazine; Olsalazine; Sulfasalazine; Corticosteroids: inflammatory bowel disease; Budesonide: inflammatory bowel disease; Budesonide: Crohn's; Beclometasone dipropionate: ulcerative colitis; Ciclosporin: ulcerative colitis; Mercaptopurine: inflammatory bowel disease; Methotrexate: Crohn's disease; Infliximab: Crohn's disease; Infliximab: ulcerative colitis; Adalimumab: Crohn's disease; Adalimumab: ulcerative colitis; Azathioprine: inflammatory bowel disease; Crohn's disease: fistulating; Metronidazole: Crohn's disease; Ciprofloxacin: Crohn's disease; Azathioprine: inflammatory bowel disease; Mercaptopurine: inflammatory bowel disease; Infliximab: Crohn's disease; Adalimumab: Crohn's disease" /><title>Inflammatory bowel disease: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP479-inflammatory-bowel-disease.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP479-inflammatory-bowel-disease.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP479-inflammatory-bowel-disease.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 12 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP271-gastro-intestinal-system.htm">1 Gastro-intestinal system</a> &gt; <a href="PHP478-chronic-bowel-disorders.htm">1.5 Chronic bowel disorders</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP478-chronic-bowel-disorders.htm" title="Previous: 1.5 Chronic bowel disorders">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP483-clostridium-difficile-infection.htm" title="Next: Clostridium difficile infection">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1>Inflammatory bowel disease</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p>Chronic inflammatory bowel diseases include <em>ulcerative colitis</em> and <em>Crohn's disease</em>. Effective management requires drug therapy, attention to nutrition, and in severe or chronic active disease, surgery. </p><p><strong>Aminosalicylates</strong> (balsalazide, mesalazine, olsalazine, and sulfasalazine), <strong>corticosteroids</strong> (hydrocortisone, beclometasone, budesonide, and prednisolone), and <strong>drugs that affect the immune response</strong> are used in the treatment of inflammatory bowel disease.</p><div><h2>Treatment of acute ulcerative colitis and Crohn's disease</h2><p>Acute mild to moderate disease affecting the rectum (proctitis) or the recto-sigmoid is treated initially with local application of an aminosalicylate (<a title="BNF:sub-section: Aminosalicylates" href="PHP487-aminosalicylates.htm">section 1.5.1</a>); alternatively, a local corticosteroid can be used but it is less effective. A combination of a local aminosalicylate and a local corticosteroid can be used for proctitis that does not respond to a local aminosalicylate alone. Foam preparations and suppositories are especially useful when patients have difficulty retaining liquid enemas.</p><p>Diffuse inflammatory bowel disease or disease that does not respond to local therapy requires oral treatment. Mild disease affecting the proximal colon can be treated with an oral aminosalicylate alone; a combination of a local and an oral aminosalicylate can be used in proctitis or distal colitis. Refractory or moderate inflammatory bowel disease usually requires adjunctive use of an oral corticosteroid such as <strong>prednisolone</strong> (<a title="BNF:monograph: PREDNISOLONE" href="PHP519-prednisolone.htm">section 1.5.2</a>) for 4–8 weeks. Modified-release <strong>budesonide</strong> is licensed for Crohn's disease affecting the ileum and the ascending colon; it causes fewer systemic side-effects than oral prednisolone but may be less effective. <strong>Beclometasone dipropionate</strong> by mouth is licensed as an adjunct to mesalazine for mild to moderate ulcerative colitis, but it is not known whether it is as effective as other corticosteroids.</p><p>Severe inflammatory bowel disease or disease that is not responding to an oral corticosteroid requires hospital admission and treatment with an intravenous corticosteroid (such as <a title="monograph: HYDROCORTISONE" href="PHP4366-hydrocortisone.htm">hydrocortisone</a> or <a title="monograph: METHYLPREDNISOLONE" href="PHP4371-methylprednisolone.htm">methylprednisolone</a>); other therapy may include intravenous fluid and electrolyte replacement, and possibly parenteral nutrition. Specialist supervision is required for patients who fail to respond adequately to these measures. Patients with severe ulcerative colitis that has not responded to intravenous corticosteroids, may benefit from a short course of intravenous <strong>ciclosporin</strong> [unlicensed indication] (<a title="BNF:monograph: CICLOSPORIN" href="PHP529-ciclosporin.htm">section 1.5.3</a>). Patients with unresponsive or chronically active Crohn's disease may benefit from <strong>azathioprine</strong> (<a title="BNF:monograph: AZATHIOPRINE" href="PHP527-azathioprine.htm">section 1.5.3</a>), <strong>mercaptopurine</strong> (<a title="BNF:monograph: MERCAPTOPURINE" href="PHP531-mercaptopurine.htm">section 1.5.3</a>) [unlicensed indication], or once-weekly <strong>methotrexate</strong> (<a title="BNF:monograph: METHOTREXATE" href="PHP533-methotrexate.htm">section 1.5.3</a>) [unlicensed indication]; these drugs have a slower onset of action.</p><p><strong>Infliximab</strong> (<a title="BNF:monograph: INFLIXIMAB" href="PHP538-infliximab.htm">section 1.5.3</a>) is licensed for the management of severe active Crohn's disease and severe ulcerative colitis in patients whose condition has not responded adequately to treatment with a corticosteroid and a conventional drug that affects the immune response, or who are intolerant of them.</p> <div id="PHP480" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Infliximab and adalimumab for Crohn's disease (May 2010)</h3><p>Infliximab or adalimumab is recommended for the treatment of severe active Crohn's disease that has not responded to conventional therapy (including corticosteroids and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contra-indications; infliximab can also be used in a similar way in children over 6 years of age. In adults over 18 years of age, infliximab is recommended for the treatment of fistulating Crohn's disease that has not responded to conventional therapy (including antibacterials, drainage, and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contra-indications.</p><p>Infliximab or adalimumab should be given as a planned course of treatment for 12 months or until treatment failure, whichever is shorter. Treatment should be continued beyond 12 months only if there is evidence of active disease—in these cases the need for treatment should be reviewed at least annually. If the disease relapses after stopping treatment, adalimumab or infliximab can be restarted [but see <a title="BNF:monograph: INFLIXIMAB" href="PHP538-infliximab.htm">Hypersensitivity Reactions</a> under Infliximab].</p><p><a href="http://www.nice.org.uk/TA187">www.nice.org.uk/TA187</a></p></div> <div id="PHP19146" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Infliximab for subacute manifestations of ulcerative colitis (April 2008)</h3><p>Infliximab is <strong>not</strong> recommended for the treatment of subacute manifestations of moderate to severe active ulcerative colitis that would normally be managed in an outpatient setting.</p><p><a href="http://www.nice.org.uk/TA140">www.nice.org.uk/TA140</a></p></div><div id="PHP19147" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Infliximab for acute exacerbations of ulcerative colitis (December 2008)</h3><p>Infliximab is recommended as an option for the treatment of acute exacerbations of severe ulcerative colitis when treatment with ciclosporin is contra-indicated or inappropriate.</p><p><a href="http://www.nice.org.uk/TA163">www.nice.org.uk/TA163</a></p></div>  <p id="PHP481"><strong>Adalimumab</strong> (<a title="BNF:monograph: ADALIMUMAB" href="PHP536-adalimumab.htm">section 1.5.3</a>) is licensed for the treatment of severe active Crohn's disease and severe ulcerative colitis in patients whose condition has not responded adequately to treatment with a corticosteroid and a conventional drug that affects the immune response, or who are intolerant of them. For inducing remission, adalimumab can be used in combination with a corticosteroid, but it may be given alone if a corticosteroid is inappropriate or is not tolerated. Adalimumab may also be used for Crohn's disease in patients who have relapsed while taking infliximab or who cannot tolerate infliximab because of hypersensitivity reactions.</p> </div><div><h2>Maintenance of remission of acute ulcerative colitis and Crohn's disease</h2><p>Smoking cessation (<a title="BNF:sub-section: Cigarette smoking" href="PHP3188-nicotine-dependence.htm">section 4.10.2</a>) reduces the risk of relapse in Crohn's disease and should be encouraged. <strong>Aminosalicylates</strong> are efficacious in the maintenance of remission of ulcerative colitis, but there is no evidence of efficacy in the maintenance of remission of Crohn's disease. Corticosteroids are <strong>not</strong> suitable for maintenance treatment because of their side-effects. In resistant or frequently relapsing cases either <strong>azathioprine</strong> (<a title="BNF:monograph: AZATHIOPRINE" href="PHP527-azathioprine.htm">section 1.5.3</a>) or <strong>mercaptopurine</strong> (<a title="BNF:monograph: MERCAPTOPURINE" href="PHP531-mercaptopurine.htm">section 1.5.3</a>) [unlicensed indication], given under close supervision may be helpful. Methotrexate (<a title="BNF:monograph: METHOTREXATE" href="PHP533-methotrexate.htm">section 1.5.3</a>) is tried in Crohn's disease if azathioprine or mercaptopurine cannot be used [unlicensed indication]. Maintenance therapy with infliximab should be considered for patients with Crohn's disease or ulcerative colitis who respond to the initial induction course of infliximab; fixed-interval dosing is superior to intermittent dosing. <strong>Adalimumab</strong> is licensed for maintenance therapy in Crohn's disease and ulcerative colitis.</p></div><div id="PHP482"><h2>Fistulating Crohn's disease</h2><p>Treatment may not be necessary for simple, asymptomatic perianal fistulas. <strong>Metronidazole</strong> (<a title="monograph: METRONIDAZOLE" href="PHP3647-metronidazole.htm">section 5.1.11</a>) or <strong>ciprofloxacin</strong> (<a title="monograph: CIPROFLOXACIN" href="PHP3665-ciprofloxacin.htm">section 5.1.12</a>) can improve symptoms of fistulating Crohn's disease but complete healing occurs rarely [unlicensed indication]. Metronidazole by mouth is used at a dose of 10–20 mg/kg daily in divided doses (usual dose 400–500 mg 3 times daily); it is usually given for 1 month but no longer than 3 months because of concerns about peripheral neuropathy. Ciprofloxacin by mouth is given at a dose of 500 mg twice daily. Other antibacterials should be given if specifically indicated (e.g. sepsis associated with fistulas and perianal disease) and for managing bacterial overgrowth in the small bowel. Fistulas may also require surgical exploration and local drainage.</p><p>Either <strong>azathioprine</strong> or <strong>mercaptopurine</strong> is used as a second-line treatment for fistulating Crohn's disease and continued for maintenance [unlicensed indication]. <strong>Infliximab</strong> is used for fistulating Crohn's disease refractory to conventional treatments; fixed-interval dosing is superior to intermittent dosing. Maintenance therapy with infliximab should be considered for patients who respond to the initial induction course of infliximab. <strong>Adalimumab</strong> can be used if there is intolerance to infliximab [unlicensed indication]</p></div><div><h2>Adjunctive treatment of inflammatory bowel disease</h2><p>Due attention should be paid to diet; high-fibre or low-residue diets should be used as appropriate.</p><p>Antimotility drugs such as codeine and loperamide, and antispasmodic drugs may precipitate paralytic ileus and megacolon in active ulcerative colitis; treatment of the inflammation is more logical. An osmotic laxative, such as a macrogol, may be required in proctitis (<a title="1.6.4 Osmotic laxatives" href="PHP610-osmotic-laxatives.htm">section 1.6.4</a>). Diarrhoea resulting from the loss of bile-salt absorption (e.g. in terminal ileal disease or bowel resection) may improve with <strong>colestyramine</strong> (<a title=" Bile acid sequestrants" href="PHP726-bile-acid-sequestrants.htm">section 1.9.2</a>), which binds bile salts.</p></div></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP478-chronic-bowel-disorders.htm">Previous: 1.5 Chronic bowel disorders</a> | <a class="top" href="PHP479-inflammatory-bowel-disease.htm#">Top</a> | <a accesskey="]" href="PHP483-clostridium-difficile-infection.htm">Next: <em>Clostridium difficile</em> infection</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>